Ajanta Pharma gets USFDA observation for Paithan facility

Drug firm Ajanta Pharma today said the US health regulator has issued one observation for its Paithan facility in Aurangabad after the inspection.

"This is to inform that our Paithan facility was recently inspected by the US FDA and we are issued one procedural related 483," Ajanta Pharma said in a BSE filing.

It further said: "We are in process of responding to the same within the stipulated time prescribed by US FDA." Shares of Ajanta Pharma were trading 1.84 per cent higher at Rs 1,791.50 on the BSE.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)